Veralipride
Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.
Product Specifications
CAS Number
66644-81-3
Product Name Alternative
(±) -Veralipride; LIR166
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Veralipride.html
Purity
99.57
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(NCC1N(CC=C)CCC1)C2=CC(S(=O)(N)=O)=CC(OC)=C2OC
Molecular Formula
C17H25N3O5S
Molecular Weight
383.46
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P501
References & Citations
[1]Melis GB, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol. 1988 Nov;72 (5) :688-92.|[2]Carranza-Lira S, et al. Actual status of veralipride use. Clin Interv Aging. 2010 Sep 7;5:271-6.|[3]Valencia MH, e al. Safety of veralipride for the treatment of vasomotor symptoms of menopause. Menopause. 2014 May;21 (5) :484-92.|[4]Franchignoni FP, et al. Parkinson syndrome induced by veralipride. Minerva Ginecol. 1995 Jun;47 (6) :277-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC743201-500 1x 500 µL
CD137 / 4-1BB / TNFRSF9 (4-1BB/3201), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details ![Purified Anti-Human CD33 Antibody[6C5]](https://cdn.genprice.uk/products/763/68dd14c4061270361e7d7340/imageurl/e-ab-f10830p.webp)
